Nateglinide and glibenclamide metabolic effects in naïve type 2 diabetic patients treated with metformin
- 1 February 2009
- journal article
- research article
- Published by Hindawi Limited in Journal of Clinical Pharmacy and Therapeutics
- Vol. 34 (1) , 13-23
Abstract
Most antidiabetic agents target only one of several underlying causes of diabetes. The complementary actions of the glinides and the biguanides may give optimal glycemic control in patients with type 2 diabetes mellitus. The aim of the present study was to compare the effects of nateglinide plus metformin with glibenclamide plus metformin on glucose and lipid metabolism, and haemodynamic parameters in patients with type 2 diabetes mellitus. We enrolled 248 type 2 diabetic patients. Patients were randomly assigned to receive nateglinide (n = 124) or glibenclamide (n = 124), after 6 months of run-in, in which we titrated nateglinide (starting dose 180 mg/day), glibenclamide (starting dose 7.5 mg/day), and metformin (starting dose 1500 mg/day). The final doses were (mean +/- standard deviation), 300 +/- 60, 12.5 +/- 2.5, and 2500 +/- 500 mg/day, respectively. We followed these patients for 1 year after titration. We assessed body mass index (BMI), fasting (FPG) and post-prandial (PPG) plasma glucose, glycosylated haemoglobin (HbA(1c)), fasting (FPI) and post-prandial (PPI) plasma insulin, homeostasis model assessment (HOMA) index, and lipid profile [total cholesterol (TC), low density lipoprotein-cholesterol (LDL-C), high density lipoprotein-cholesterol (HDL-C), triglycerides (Tg), apolipoprotein A-I (Apo A-I), and apolipoprotein B (Apo B)], systolic blood pressure (SBP), and diastolic blood pressure (DBP). All variables were evaluated at baseline and after 3 and 6 months in the run-in period, and at baseline, and after 3, 6, 9 and 12 months for both treatment groups. Body mass index did not show any significant change during the study. We observed a significant improvement from baseline to 1 year on HbA(1c) (P < 0.01 vs. baseline and vs. glibenclamide group, respectively), FPG (P < 0.01 vs. baseline), PPG (P < 0.01 vs. baseline), and on HOMA index (P < 0.05 vs. baseline) in the nateglinide group. In the glibenclamide group, we found significant changes in HbA(1c) (P < 0.05 vs. baseline), FPG (P < 0.01 vs. baseline), PPG (P < 0.05 vs. baseline), and HOMA index (P < 0.05 vs. baseline). No significant change was observed in TC, LDL-C, HDL-C, Tg, Apo A-I, Apo B, SBP, DBP and HR in either group after 3, 6, 9 and 12 months. These effects of nateglinide and glibenclamide on insulin-resistance parameters are in agreement with previous reports. Contrarily to previous reports, we did not observe any significant BP change in patients treated with glibenclamide. Although both nateglinide and glibenclamide attenuated PPG and HOMA index, they did not have significant effects on lipid metabolism, as already shown in subjects with type 2 diabetes and good glycemic control. Nateglinide improved glycemic control better than glibenclamide in combination with metformin.Keywords
This publication has 34 references indexed in Scilit:
- Effect of the oral hypoglycaemic sulphonylurea glibenclamide, a blocker of ATP‐sensitive potassium channels, on walking distance in patients with intermittent claudicationDiabetic Medicine, 2006
- PRESERVE-βDiabetes Care, 2005
- Nateglinide alone or with metformin safely improves glycaemia to target in patients up to an age of 84Diabetes, Obesity and Metabolism, 2004
- Acute and long‐term effects of nateglinide on insulin secretory pathwaysBritish Journal of Pharmacology, 2004
- Efficacy and tolerability of initial combination therapy with nateglinide and metformin in treatment-naïve patients with type 2 diabetesCurrent Medical Research and Opinion, 2004
- Clinical Pharmacokinetics of NateglinideClinical Pharmacokinetics, 2004
- Efficacy, Tolerability and Safety of Nateglinide in Combination with Metformin. Results from a Study under General Practice ConditionsExperimental and Clinical Endocrinology & Diabetes, 2003
- Effects of nateglinide and glibenclamide on postprandial lipid and glucose metabolism in type 2 diabetesDiabetes/Metabolism Research and Reviews, 2002
- Enzymatische Bestimmung des Gesamtcholesterins mit dem Greiner Selective Analyzer (GSA-II)Clinical Chemistry and Laboratory Medicine (CCLM), 1977
- Determination of total serum insulin (IRI) in insulin-treated diabetic patientsDiabetologia, 1972